Hemophilia Treatment Recommendations and Cost Management for Managed Care and Specialty Pharmacy Web Activity

Release Date: September 1, 2018
Expiration Date: February 29, 2020
Estimated Time to Complete Activity: 1.25 hours
Compatible with all modern browsers and mobile devices

EXPERT FACULTY


	Mark T. Reding, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation Director, Center for Bleeding and Clotting Disorders University of Minnesota Medical Center Click here for biography

	Michael Zeglinski, RPh Senior Vice President, Specialty Pharmacy OptumRx^®/BriovaRx^® Click here for biography

TARGET AUDIENCE

Managed care pharmacy directors, clinical pharmacists, quality directors, specialty pharmacists, medical directors, care managers, registered nurses, and other managed care and payer organization professionals

STATEMENT OF NEED/PROGRAM OVERVIEW
Hemophilia is a high cost chronic condition with total annual costs that can average $250,000 or more for severe patients. Optimal outcomes require a collaborative and coordinated patient experience. The collaborative team can include an insurer, Hemophilia Treatment Center (HTC), and specialty pharmacy. Specialty pharmacy services can support patient adherence to treatment and assist physicians, plans, and employers in meeting clinical and/or financial goals. The activity provides an advanced clinical update and emphasizes the need for well‐coordinated treatment management, best practices to integrate hemophilia care with payer policies, and the value of having collaboration among all stakeholders.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

Describe recent insights into the safety, efficacy, and attributes of recently approved and emerging hemophilia treatment options

Align recently approved therapies into the current hemophilia treatment algorithm
Explain hemophilia‐related complications associated with inhibitor development and its significant clinical and economic consequences
Apply processes for managed care organizations and specialty pharmacy providers to improve communications and collaborations with hemophilia treatment centers (HTCs)

ACCREDITATION INFORMATION

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the National Hemophilia Foundation, and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number – JA4008162-9999-18-246-H01-P
Type of Activity: Application

For Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to the CPE Monitor as required. After receipt of a completed activity evaluation form, you will be provided with instructions to have your credit immediately uploaded to the CPE Monitor.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Mark T. Reding, MD	Consulting Fees (ex. advisory boards) – Bayer, Bioverativ, Genentech, Inc., Novo Nordisk, Inc., Shire Fees for Non‐CME/CE Services Received Directly from a Commercial Interest or their Agents (ex. speakers’ bureaus) – Bioverativ, Shire Contracted Research – Bayer
Michael Zeglinski, RPh	No financial interest/relationships relating to the topic of this activity

The PIM planners and managers have nothing to disclose. The Impact Education, LLC and National Hemophilia Foundation planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of September 1, 2018, through February 29, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.